Faith E. Davies, MD

Articles

Dr. Davies on Isatuximab-Based Combinations in Relapsed/Refractory Multiple Myeloma

July 6th 2021

Faith Davies, MD, discusses the approval of isatuximab-irfc-based combinations for patients with relapsed/refractory multiple myeloma.

Dr. Davies on the Next Steps for CAR T-Cell Therapy in Relapsed/Refractory Myeloma

July 1st 2021

Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Davies on Future Research Directions With Isatuximab in Multiple Myeloma

June 16th 2021

Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.

Dr. Davies on Key Considerations for Early-Relapse Multiple Myeloma

June 3rd 2021

Faith Davies, MD, discusses key considerations for developing a treatment strategy for patients with early-relapse multiple myeloma.

Dr. Davies on Personalizing Treatment in Relapsed/Refractory Myeloma

June 9th 2020

Faith E. Davies, MD, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.

Dr. Davies on Research Efforts in Lenalidomide-Refractory Myeloma

April 21st 2020

Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.

Dr. Davies on the Use of Carfilzomib in Multiple Myeloma

April 14th 2020

Faith E. Davies, MD, discusses the dosing of carfilzomib in the treatment of patients with multiple myeloma.

Dr. Davies on Promise of Venetoclax in Relapsed/Refractory Myeloma

April 13th 2020

Faith E. Davies, MD, discusses the use of venetoclax as a precision medicine approach in patients with relapsed/refractory multiple myeloma.